Does the media favor CADL or GRAL?

In the previous week, GRAIL had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 16 mentions for GRAIL and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat GRAIL's score of 0.65 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive GRAIL 3 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CADL or DNLI more profitable?

Denali Therapeutics' return on equity of -55.27% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% Denali Therapeutics N/A -55.27% -44.24%

Does the media favor CADL or DNLI?

In the previous week, Denali Therapeutics had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for Denali Therapeutics and 1 mentions for Candel Therapeutics. Denali Therapeutics' average media sentiment score of 1.12 beat Candel Therapeutics' score of 0.71 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CADL or ABCL?

In the previous week, AbCellera Biologics had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat AbCellera Biologics' score of 0.35 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbCellera Biologics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer CADL or GMTX?

Candel Therapeutics presently has a consensus target price of $19.29, suggesting a potential upside of 77.99%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Candel Therapeutics is more favorable than Gemini Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 1 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.64 Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings & valuation, CADL or GMTX?

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$1.41 N/A Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A

Is CADL or GMTX more profitable?

Gemini Therapeutics' return on equity of -38.78% beat Candel Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -76.98% -48.50% Gemini Therapeutics N/A -38.78% -35.88%

Does the media favor CADL or IDYA?

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 1 mentions for Candel Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.85 beat Candel Therapeutics' score of 0.71 indicating that IDEAYA Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive IDEAYA Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Candel Therapeutics (CADL) Competitors

$10.84 -0.51 (-4.45%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$10.84 0.00 (0.00%)

As of 09/18/2026 07:30 PM Eastern

Compare

CADL vs. GRAL, DNLI, ABCL, GMTX, and IDYA

Should you buy Candel Therapeutics stock or one of its competitors? Candel Therapeutics's main competitors and comparable companies include GRAIL (GRAL), Denali Therapeutics (DNLI), AbCellera Biologics (ABCL), Gemini Therapeutics (GMTX), and IDEAYA Biosciences (IDYA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Candel Therapeutics compare to GRAIL?

Candel Therapeutics (NASDAQ:CADL) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Candel Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market. Comparatively, GRAIL has a beta of 3.25, suggesting that its share price is 225% more volatile than the broader market.

Candel Therapeutics has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
GRAIL	$147.17M	24.52	-$408.35M	-$9.75	N/A

In the previous week, GRAIL had 15 more articles in the media than Candel Therapeutics. MarketBeat recorded 16 mentions for GRAIL and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat GRAIL's score of 0.65 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GRAIL	3 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics presently has a consensus target price of $19.29, indicating a potential upside of 77.99%. GRAIL has a consensus target price of $70.30, indicating a potential downside of 12.96%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Candel Therapeutics is more favorable than GRAIL.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
GRAIL	1 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

13.9% of Candel Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 1.8% of GRAIL shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to GRAIL's net margin of -236.95%. GRAIL's return on equity of -15.88% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
GRAIL	-236.95%	-15.88%	-14.02%

Summary

Candel Therapeutics beats GRAIL on 10 of the 15 factors compared between the two stocks.

How does Candel Therapeutics compare to Denali Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

In the previous week, Denali Therapeutics had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for Denali Therapeutics and 1 mentions for Candel Therapeutics. Denali Therapeutics' average media sentiment score of 1.12 beat Candel Therapeutics' score of 0.71 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 14.3% of Candel Therapeutics shares are held by insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Candel Therapeutics currently has a consensus target price of $19.29, suggesting a potential upside of 77.99%. Denali Therapeutics has a consensus target price of $35.85, suggesting a potential upside of 81.78%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Denali Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Candel Therapeutics has a beta of -0.48, meaning that its share price is 148% less volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Denali Therapeutics' return on equity of -55.27% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Denali Therapeutics	N/A	-55.27%	-44.24%

Candel Therapeutics has higher earnings, but lower revenue than Denali Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Denali Therapeutics	$330.53M	9.54	-$512.54M	-$2.84	N/A

Summary

Denali Therapeutics beats Candel Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Candel Therapeutics compare to AbCellera Biologics?

Candel Therapeutics (NASDAQ:CADL) and AbCellera Biologics (NASDAQ:ABCL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Candel Therapeutics presently has a consensus target price of $19.29, indicating a potential upside of 77.99%. AbCellera Biologics has a consensus target price of $12.83, indicating a potential upside of 1.61%. Given Candel Therapeutics' higher possible upside, equities analysts plainly believe Candel Therapeutics is more favorable than AbCellera Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
AbCellera Biologics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Candel Therapeutics has a net margin of 0.00% compared to AbCellera Biologics' net margin of -248.83%. AbCellera Biologics' return on equity of -17.49% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
AbCellera Biologics	-248.83%	-17.49%	-12.36%

Candel Therapeutics has a beta of -0.48, suggesting that its share price is 148% less volatile than the broader market. Comparatively, AbCellera Biologics has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 61.4% of AbCellera Biologics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 28.4% of AbCellera Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Candel Therapeutics has higher earnings, but lower revenue than AbCellera Biologics. AbCellera Biologics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
AbCellera Biologics	$75.13M	51.54	-$146.41M	-$0.54	N/A

In the previous week, AbCellera Biologics had 2 more articles in the media than Candel Therapeutics. MarketBeat recorded 3 mentions for AbCellera Biologics and 1 mentions for Candel Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat AbCellera Biologics' score of 0.35 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbCellera Biologics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

AbCellera Biologics beats Candel Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Candel Therapeutics compare to Gemini Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Gemini Therapeutics (NASDAQ:GMTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, valuation, dividends, risk and institutional ownership.

Gemini Therapeutics' return on equity of -38.78% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
Gemini Therapeutics	N/A	-38.78%	-35.88%

Candel Therapeutics presently has a consensus target price of $19.29, suggesting a potential upside of 77.99%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Candel Therapeutics is more favorable than Gemini Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Gemini Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Candel Therapeutics had 1 more articles in the media than Gemini Therapeutics. MarketBeat recorded 1 mentions for Candel Therapeutics and 0 mentions for Gemini Therapeutics. Candel Therapeutics' average media sentiment score of 0.71 beat Gemini Therapeutics' score of 0.00 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Candel Therapeutics	Positive
Gemini Therapeutics	Neutral

Gemini Therapeutics is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A

Candel Therapeutics has a beta of -0.48, meaning that its share price is 148% less volatile than the broader market. Comparatively, Gemini Therapeutics has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 75.4% of Gemini Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by insiders. Comparatively, 12.9% of Gemini Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Candel Therapeutics beats Gemini Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Candel Therapeutics compare to IDEAYA Biosciences?

Candel Therapeutics (NASDAQ:CADL) and IDEAYA Biosciences (NASDAQ:IDYA) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership, analyst recommendations and media sentiment.

Candel Therapeutics has a beta of -0.48, suggesting that its stock price is 148% less volatile than the broader market. Comparatively, IDEAYA Biosciences has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 98.3% of IDEAYA Biosciences shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 4.7% of IDEAYA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Candel Therapeutics has a net margin of 0.00% compared to IDEAYA Biosciences' net margin of -75.93%. IDEAYA Biosciences' return on equity of -16.73% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-76.98%	-48.50%
IDEAYA Biosciences	-75.93%	-16.73%	-15.34%

In the previous week, IDEAYA Biosciences had 3 more articles in the media than Candel Therapeutics. MarketBeat recorded 4 mentions for IDEAYA Biosciences and 1 mentions for Candel Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.85 beat Candel Therapeutics' score of 0.71 indicating that IDEAYA Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
IDEAYA Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics presently has a consensus target price of $19.29, suggesting a potential upside of 77.99%. IDEAYA Biosciences has a consensus target price of $52.69, suggesting a potential upside of 37.18%. Given Candel Therapeutics' higher probable upside, equities research analysts plainly believe Candel Therapeutics is more favorable than IDEAYA Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Candel Therapeutics has higher earnings, but lower revenue than IDEAYA Biosciences. IDEAYA Biosciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A
IDEAYA Biosciences	$218.71M	15.43	-$113.70M	-$1.94	N/A

Summary

IDEAYA Biosciences beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Candel Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CADL vs. The Competition

Export

Metric	Candel Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$867.72M	$3.91B	$7.25B	$13.13B
Dividend Yield	N/A	3.65%	2.57%	12.94%
P/E Ratio	-7.68	14.08	273.81	25.39
Price / Sales	N/A	1,407.75	692.78	109.00
Price / Cash	N/A	110.75	77.42	51.66
Price / Book	11.41	15.45	10.45	6.33
Net Income	-$38.18M	-$22.78M	$3.48B	$358.24M
7 Day Performance	2.70%	-1.22%	0.88%	1.17%
1 Month Performance	-19.74%	-4.44%	-1.59%	-2.59%
1 Year Performance	125.26%	37.78%	18.08%	5.97%

Candel Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CADL Candel Therapeutics	3.317 of 5 stars	$10.84 -4.5%	$19.29 +78.0%	+119.3%	$867.72M	N/A	N/A	55	High Trading Volume
GRAL GRAIL	0.8435 of 5 stars	$80.48 +0.2%	$67.78 -15.8%	+104.0%	$3.59B	$147.17M	N/A	1,360	News Coverage Analyst Upgrade
DNLI Denali Therapeutics	3.7288 of 5 stars	$21.70 -2.6%	$35.85 +65.2%	+49.6%	$3.47B	$330.53M	N/A	430	Positive News Analyst Upgrade
ABCL AbCellera Biologics	1.4178 of 5 stars	$11.20 -2.0%	$12.83 +14.6%	+167.6%	$3.43B	$75.13M	N/A	500	Positive News
GMTX Gemini Therapeutics	N/A	$79.23 -0.2%	N/A	+13.3%	$3.43B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CADL) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Candel Therapeutics (CADL) Competitors

CADL vs. GRAL, DNLI, ABCL, GMTX, and IDYA

How does Candel Therapeutics compare to GRAIL?

Summary

How does Candel Therapeutics compare to Denali Therapeutics?

Summary

How does Candel Therapeutics compare to AbCellera Biologics?

Summary

How does Candel Therapeutics compare to Gemini Therapeutics?

Summary

How does Candel Therapeutics compare to IDEAYA Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Candel Therapeutics (CADL) Competitors

CADL vs. GRAL, DNLI, ABCL, GMTX, and IDYA

How does Candel Therapeutics compare to GRAIL?

Which has more volatility & risk, CADL or GRAL?

Which has better earnings and valuation, CADL or GRAL?

Does the media favor CADL or GRAL?

Do analysts rate CADL or GRAL?

Do institutionals and insiders believe in CADL or GRAL?

Is CADL or GRAL more profitable?

Summary

How does Candel Therapeutics compare to Denali Therapeutics?

Does the media favor CADL or DNLI?

Do institutionals and insiders believe in CADL or DNLI?

Do analysts prefer CADL or DNLI?

Which has more risk and volatility, CADL or DNLI?

Is CADL or DNLI more profitable?

Which has higher earnings and valuation, CADL or DNLI?

Summary

How does Candel Therapeutics compare to AbCellera Biologics?

Do analysts rate CADL or ABCL?

Is CADL or ABCL more profitable?

Which has more volatility and risk, CADL or ABCL?

Do insiders & institutionals believe in CADL or ABCL?

Which has better valuation and earnings, CADL or ABCL?

Does the media refer more to CADL or ABCL?

Summary

How does Candel Therapeutics compare to Gemini Therapeutics?

Is CADL or GMTX more profitable?

Do analysts prefer CADL or GMTX?

Does the media favor CADL or GMTX?

Which has higher earnings & valuation, CADL or GMTX?

Which has more volatility and risk, CADL or GMTX?

Do insiders and institutionals have more ownership in CADL or GMTX?

Summary

How does Candel Therapeutics compare to IDEAYA Biosciences?

Which has more risk & volatility, CADL or IDYA?

Do insiders & institutionals hold more shares of CADL or IDYA?

Is CADL or IDYA more profitable?

Does the media favor CADL or IDYA?

Do analysts rate CADL or IDYA?

Which has stronger valuation & earnings, CADL or IDYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CADL vs. The Competition

Candel Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools